Proteinuria  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01192399: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Completed
2
29
NA
Eculizumab, Soliris
Alexion Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
06/08
06/08
EAGLE, NCT02093533: Eculizumab in Primary MPGN

Completed
2
10
Europe
Eculizumab, Soliris
Mario Negri Institute for Pharmacological Research, Alexion Pharma Italy s.r.l.
Membranoproliferative Glomerulonephritis
12/17
12/17

Download Options